Tecrea Ltd recently had the pleasure of hosting the iPaper team to discuss the ongoing UTI project. Tecrea Ltd is developing a novel dual-action, non-antibiotic antimicrobial therapy designed to both combat infection and alleviate UTI symptoms through localized administration. This innovative treatment is being developed in collaboration with the Bladder Infection and Immunity Group (BIIG) at University College London (UCL), led by renowned chronic UTI specialists Dr. Rajvinder Khasriya and Dr. Harry Horsley.
Urinary tract infections affect over 404 million people globally each year. Approximately 60% of women will experience at least one UTI in their lifetime, with 30–40% suffering from recurrent infections. In the UK alone, this equates to around 6 million women living with recurrent UTIs.
Click here to read the full article.
This news post is for informational purposes only and does not constitute a formal publication or scientific endorsement of the technologies mentioned.